FAAS
MRTX

First Allied Advisory Services’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

First Allied Advisory Services’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,400
Closed -$302K – 1215
2018
Q3 		$302K Buy
+6,400
New +$356K 0.01% 903

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Allied Advisory Services's MRTX Position: Q4 2018 in Review

First Allied Advisory Services sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 6,400 shares — an estimated $302K sold.

First Allied Advisory Services first reported a position in MRTX in Q3 2018 and held it in 1 quarter. The position peaked at $302K in Q3 2018. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • First Allied Advisory Services reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • First Allied Advisory Services sold 6,400 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $302K.
  • First Allied Advisory Services first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • First Allied Advisory Services's Mirati Therapeutics, Inc. Common Stock position peaked at $302K in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on First Allied Advisory Services's 13F filing for Q4 2018, filed 15 Feb 2019.